8-K filing — PAVmed Inc. (PAVM)
Filed: 2026-09-10 AccNo: 0001493152-26-042021 Size: 576 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Stocks · News reference
PAVmed Entered At-The-Market Equity Sales Agreement For Up To $9.4M Of Stock
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Nvidia To Rally Around 146%? Here Are 10 Top Analyst Forecasts For Thursday
Wall Street analysts changed outlook on top names: Evercore raised Salesforce target, Needham raised Nutanix target, Ascendiant raised PAVmed target, Cantor raised Okta target, Piper raised Veeva target, Cantor boosted Solid Biosciences target, BTIG raised Crowdstrike target, Cantor cut Dycom target.
Ascendiant Capital Maintains Buy on PAVmed, Raises Price Target to $57
Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:PAVM) with a Buy and raises the price target from $56 to $57.